Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells

Dalin He, Zhao Mei Mu, Xiaofeng Le, Jer Tsong Hsieh, Rey Chen Pong, Leland W K Chung, Kun Sang Chang

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Our previous studies demonstrated that the promyelocytic leukemia gene, PML, encodes a growth and transformation suppressor. Overexpression of PML inhibits cancer cell growth in vitro and in vivo. In this study, we further explored the possibility of applying PML as a potential agent for developing prostate cancer gene therapy using an adenovirus delivery system. We have constructed and produced the recombinant PML-adenovirus, Ad-PML in which the full-length PML cDNA is driven by the strong cytomegalovirus promoter. In LNCaP, DU145, and PC-3 prostate cancer cell lines, an infection efficiency of 90% can be achieved at a concentration of 2, 10, and 10 multiplicity of infection (MOI), respectively. Western blotting and immunofluorescence staining demonstrated that the AD-PML-infected cells expressed a high level of PML protein. The protein expression peaked at days 3-4 postinfection, and a detectable level of PML was found at day 18 after viral infection. To test the effect of Ad-PML on the growth of prostate cancer cells, the DU145 and LNCaP cells were infected with 10 and 2 MO1 of Ad-PML. We found that the growth rate of the Ad-PML-infected DU145 and LNCaP cells were significantly inhibited, A tumorigenicity test in nude mice showed that the Ad-PML-treated DU145 cells failed to form tumors. Most importantly, direct injection of Ad- PML into DU145-induced tumors was able to repress tumor growth in nude mice by 64%. Taken together, these data indicate that PML is a tumor growth suppressor in prostate cancer and that Ad-PML may he a potential candidate for human prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)1868-1872
Number of pages5
JournalCancer Research
Volume57
Issue number10
StatePublished - May 15 1997

Fingerprint

Adenoviridae
Prostatic Neoplasms
Growth
Neoplasms
Nude Mice
Carcinogenicity Tests
Neoplasm Genes
Virus Diseases
Infection
Cytomegalovirus
Genetic Therapy
Fluorescent Antibody Technique
Leukemia
Proteins
Complementary DNA
Western Blotting
Staining and Labeling
Cell Line
Injections
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

He, D., Mu, Z. M., Le, X., Hsieh, J. T., Pong, R. C., Chung, L. W. K., & Chang, K. S. (1997). Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Research, 57(10), 1868-1872.

Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. / He, Dalin; Mu, Zhao Mei; Le, Xiaofeng; Hsieh, Jer Tsong; Pong, Rey Chen; Chung, Leland W K; Chang, Kun Sang.

In: Cancer Research, Vol. 57, No. 10, 15.05.1997, p. 1868-1872.

Research output: Contribution to journalArticle

He, D, Mu, ZM, Le, X, Hsieh, JT, Pong, RC, Chung, LWK & Chang, KS 1997, 'Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells', Cancer Research, vol. 57, no. 10, pp. 1868-1872.
He, Dalin ; Mu, Zhao Mei ; Le, Xiaofeng ; Hsieh, Jer Tsong ; Pong, Rey Chen ; Chung, Leland W K ; Chang, Kun Sang. / Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. In: Cancer Research. 1997 ; Vol. 57, No. 10. pp. 1868-1872.
@article{779abec972684331ad8ac56714f2a01c,
title = "Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells",
abstract = "Our previous studies demonstrated that the promyelocytic leukemia gene, PML, encodes a growth and transformation suppressor. Overexpression of PML inhibits cancer cell growth in vitro and in vivo. In this study, we further explored the possibility of applying PML as a potential agent for developing prostate cancer gene therapy using an adenovirus delivery system. We have constructed and produced the recombinant PML-adenovirus, Ad-PML in which the full-length PML cDNA is driven by the strong cytomegalovirus promoter. In LNCaP, DU145, and PC-3 prostate cancer cell lines, an infection efficiency of 90{\%} can be achieved at a concentration of 2, 10, and 10 multiplicity of infection (MOI), respectively. Western blotting and immunofluorescence staining demonstrated that the AD-PML-infected cells expressed a high level of PML protein. The protein expression peaked at days 3-4 postinfection, and a detectable level of PML was found at day 18 after viral infection. To test the effect of Ad-PML on the growth of prostate cancer cells, the DU145 and LNCaP cells were infected with 10 and 2 MO1 of Ad-PML. We found that the growth rate of the Ad-PML-infected DU145 and LNCaP cells were significantly inhibited, A tumorigenicity test in nude mice showed that the Ad-PML-treated DU145 cells failed to form tumors. Most importantly, direct injection of Ad- PML into DU145-induced tumors was able to repress tumor growth in nude mice by 64{\%}. Taken together, these data indicate that PML is a tumor growth suppressor in prostate cancer and that Ad-PML may he a potential candidate for human prostate cancer therapy.",
author = "Dalin He and Mu, {Zhao Mei} and Xiaofeng Le and Hsieh, {Jer Tsong} and Pong, {Rey Chen} and Chung, {Leland W K} and Chang, {Kun Sang}",
year = "1997",
month = "5",
day = "15",
language = "English (US)",
volume = "57",
pages = "1868--1872",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells

AU - He, Dalin

AU - Mu, Zhao Mei

AU - Le, Xiaofeng

AU - Hsieh, Jer Tsong

AU - Pong, Rey Chen

AU - Chung, Leland W K

AU - Chang, Kun Sang

PY - 1997/5/15

Y1 - 1997/5/15

N2 - Our previous studies demonstrated that the promyelocytic leukemia gene, PML, encodes a growth and transformation suppressor. Overexpression of PML inhibits cancer cell growth in vitro and in vivo. In this study, we further explored the possibility of applying PML as a potential agent for developing prostate cancer gene therapy using an adenovirus delivery system. We have constructed and produced the recombinant PML-adenovirus, Ad-PML in which the full-length PML cDNA is driven by the strong cytomegalovirus promoter. In LNCaP, DU145, and PC-3 prostate cancer cell lines, an infection efficiency of 90% can be achieved at a concentration of 2, 10, and 10 multiplicity of infection (MOI), respectively. Western blotting and immunofluorescence staining demonstrated that the AD-PML-infected cells expressed a high level of PML protein. The protein expression peaked at days 3-4 postinfection, and a detectable level of PML was found at day 18 after viral infection. To test the effect of Ad-PML on the growth of prostate cancer cells, the DU145 and LNCaP cells were infected with 10 and 2 MO1 of Ad-PML. We found that the growth rate of the Ad-PML-infected DU145 and LNCaP cells were significantly inhibited, A tumorigenicity test in nude mice showed that the Ad-PML-treated DU145 cells failed to form tumors. Most importantly, direct injection of Ad- PML into DU145-induced tumors was able to repress tumor growth in nude mice by 64%. Taken together, these data indicate that PML is a tumor growth suppressor in prostate cancer and that Ad-PML may he a potential candidate for human prostate cancer therapy.

AB - Our previous studies demonstrated that the promyelocytic leukemia gene, PML, encodes a growth and transformation suppressor. Overexpression of PML inhibits cancer cell growth in vitro and in vivo. In this study, we further explored the possibility of applying PML as a potential agent for developing prostate cancer gene therapy using an adenovirus delivery system. We have constructed and produced the recombinant PML-adenovirus, Ad-PML in which the full-length PML cDNA is driven by the strong cytomegalovirus promoter. In LNCaP, DU145, and PC-3 prostate cancer cell lines, an infection efficiency of 90% can be achieved at a concentration of 2, 10, and 10 multiplicity of infection (MOI), respectively. Western blotting and immunofluorescence staining demonstrated that the AD-PML-infected cells expressed a high level of PML protein. The protein expression peaked at days 3-4 postinfection, and a detectable level of PML was found at day 18 after viral infection. To test the effect of Ad-PML on the growth of prostate cancer cells, the DU145 and LNCaP cells were infected with 10 and 2 MO1 of Ad-PML. We found that the growth rate of the Ad-PML-infected DU145 and LNCaP cells were significantly inhibited, A tumorigenicity test in nude mice showed that the Ad-PML-treated DU145 cells failed to form tumors. Most importantly, direct injection of Ad- PML into DU145-induced tumors was able to repress tumor growth in nude mice by 64%. Taken together, these data indicate that PML is a tumor growth suppressor in prostate cancer and that Ad-PML may he a potential candidate for human prostate cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031006321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031006321&partnerID=8YFLogxK

M3 - Article

C2 - 9157977

AN - SCOPUS:0031006321

VL - 57

SP - 1868

EP - 1872

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -